LENZ LENZ Therapeutics, Inc.
Nasdaq · SEC CIK 1815776 · EDGAR
- Bought, last 12 months
- $654.9K 5 purchases by 4 insiders
- Sold, last 12 months
- $10.61M 3 sales by 2 insiders
- Filings on record
- 95 since 2021-07-01, latest 2026-06-15 20:22
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Versant Vantage II GP-GP, LLC | 10% | — | $10.35M |
| Olsson Shawn | Chief Commercial Off | — | $261.0K |
| Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | $251.4K | — |
| MCCOLLUM JAMES W | Dir | $239.3K | — |
| Chevallard Daniel R. | CFO | $114.3K | — |
| George Jeffrey P. | Dir | $49.9K | — |
Transactions 56
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-30 | 2026-03-27 | LENZ | George Jeffrey P. | Dir | P - Purchase | $8.92 | +5,592 | 5,592 | New | +$49.9K | |
| 2026-03-30 | 2026-03-27 | LENZ | Chevallard Daniel R. | CFO | P - Purchase | $8.57 | +7,500 | 12.9K | +139% | +$64.3K | |
| 2026-03-30 | 2026-03-27 | LENZ | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | P - Purchase | $8.95 | +28.1K | 77.3K | +57% | +$251.4K | |
| D | 2025-11-19 | 2025-11-17 | LENZ | Olsson Shawn | Chief Commercial Off | M - OptEx | $2.08 | +10.0K | 14.7K | +211% | +$20.8K |
| DM | 2025-11-19 | 2025-11-17 | LENZ | Olsson Shawn | Chief Commercial Off | S - Sale+OE | $26.10 | -10.0K | 4,733 | -68% | -$261.0K |
| 2025-11-10 | 2025-11-07 | LENZ | MCCOLLUM JAMES W | Dir | P - Purchase | $22.79 | +10.5K | 10.5K | New | +$239.3K | |
| M | 2025-11-07 | 2025-11-07 | LENZ | Chevallard Daniel R. | CFO | P - Purchase | $22.76 | +2,198 | 3,208 | +218% | +$50.0K |
| MI | 2025-10-02 | 2025-09-30 | LENZ | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $46.01 | -92.0K | 764.1K | -11% | -$4.23M |
| M | 2025-10-02 | 2025-09-30 | LENZ | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $46.01 | -132.9K | 1.05M | -11% | -$6.12M |
| M | 2025-09-22 | 2025-09-18 | LENZ | Versant Venture Capital VI, L.P. | 10% | S - Sale | $42.23 | -90.7K | 1.18M | -7% | -$3.83M |
| MI | 2025-09-22 | 2025-09-18 | LENZ | Versant Venture Capital VI, L.P. | 10% | S - Sale | $42.23 | -44.6K | 856.3K | -5% | -$1.89M |
| M | 2025-08-26 | 2025-08-22+ | LENZ | Versant Ventures VII GP, L.P. | 10% | S - Sale | $39.47 | -126.0K | 1.32M | -9% | -$4.97M |
| MI | 2025-08-26 | 2025-08-22+ | LENZ | Versant Ventures VII GP, L.P. | 10% | S - Sale | $39.47 | -62.1K | 952.8K | -6% | -$2.45M |
| MI | 2025-08-19 | 2025-08-15+ | LENZ | Versant Venture Capital VI, L.P. | 10% | S - Sale | $39.33 | -85.0K | 962.9K | -8% | -$3.34M |
| M | 2025-08-19 | 2025-08-15+ | LENZ | Versant Venture Capital VI, L.P. | 10% | S - Sale | $39.34 | -175.7K | 1.43M | -11% | -$6.91M |
| 2025-07-14 | 2025-07-10 | LENZ | Versant Ventures VII GP-GP, LLC | 10% | S - Sale | $34.00 | -191.4K | 1.58M | -11% | -$6.51M | |
| 2025-07-01 | 2025-06-27 | LENZ | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $30.47 | -200.0K | 1.77M | -10% | -$6.09M | |
| MI | 2025-06-20 | 2025-06-18+ | LENZ | Versant Ventures VI GP, L.P. | 10% | S - Sale | $30.15 | -200.9K | 1.15M | -15% | -$6.06M |
| 2025-06-20 | 2025-06-20 | LENZ | Versant Ventures VI GP, L.P. | 10% | S - Sale | $30.25 | -133.9K | 1.97M | -6% | -$4.05M | |
| I | 2025-06-12 | 2025-06-10 | LENZ | Versant Vantage II GP-GP, LLC | 10% | S - Sale | $29.00 | -350.0K | 1.25M | -22% | -$10.15M |
| D | 2025-04-09 | 2025-04-09 | LENZ | Olsson Shawn | Chief Commercial Off | M - OptEx | $2.08 | +1,400 | 4,733 | +42% | +$2,912 |
| D | 2025-03-07 | 2025-03-07 | LENZ | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | M - OptEx | $1.04 | +4,200 | 49.2K | +9% | +$4,368 |
| D | 2024-12-17 | 2024-12-16 | LENZ | Olsson Shawn | Chief Commercial Off | M - OptEx | $2.08 | +3,333 | 3,333 | New | +$6,933 |
| D | 2024-07-23 | 2024-07-22 | LENZ | Schimmelpennink Evert B. | Pres, CEO, Sec, Dir | M - OptEx | $1.04 | +45.0K | 45.0K | New | +$46.8K |
| 2024-05-15 | 2024-05-14 | LENZ | Chevallard Daniel R. | CFO | P - Purchase | $15.68 | +3,188 | 3,188 | New | +$50.0K | |
| I | 2024-05-14 | 2024-05-13 | LENZ | MCCOLLUM JAMES W | Dir | P - Purchase | $15.99 | +31.3K | 525.6K | +6% | +$501.0K |
| DMI | 2024-03-25 | 2024-03-21 | LENZ | RA Capital Nexus Fund II, L.P. | Dir, 10% | P - Purchase | $15.03 | +998.0K | 3.32M | +43% | +$15.00M |
| DMI | 2024-03-25 | 2024-03-21 | LENZ | RA Capital Nexus Fund II, L.P. | Dir, 10% | A - Grant | — | +3.25M | 164.7K | New | — |
| I | 2024-03-25 | 2024-03-21 | LENZ | Versant Vantage II GP, L.P. | 10% | J - Other | — | +598.2K | 842.2K | +245% | — |
| D | 2024-03-25 | 2024-03-21 | LENZ | Odrich Marc | Chief Medical Off | A - Grant | $0.00 | +99.6K | 99.6K | New | $0 |
| D | 2024-03-25 | 2024-03-21 | LENZ | MCCOLLUM JAMES W | Dir | A - Grant | $0.00 | +95.0K | 95.0K | New | $0 |
| DMI | 2024-03-25 | 2024-03-21 | LENZ | MCCOLLUM JAMES W | Dir | A - Grant | $0.5058 | +494.2K | 494.2K | New | +$250.0K |
| 2022-04-13 | 2022-04-11 | LENZ | Gutry Phil | Chief BUSINESS Off | P - Purchase | $4.01 | +5,000 | 299.9K | +2% | +$20.1K | |
| MI | 2022-04-13 | 2022-04-11+ | LENZ | AKKARAJU SRINIVAS | 10% | P - Purchase | $4.08 | +424.5K | 8.11M | +6% | +$1.73M |
| MI | 2022-01-25 | 2022-01-21+ | LENZ | AKKARAJU SRINIVAS | 10% | P - Purchase | $8.94 | +123.0K | 8.01M | +2% | +$1.10M |
| MI | 2022-01-21 | 2022-01-19+ | LENZ | AKKARAJU SRINIVAS | 10% | P - Purchase | $9.10 | +97.7K | 7.91M | +1% | +$888.7K |
| I | 2021-12-20 | 2021-12-15 | LENZ | Samsara BioCapital, L.P. | 10% | P - Purchase | $10.19 | +22.3K | 7.81M | +0.3% | +$227.5K |
| I | 2021-11-24 | 2021-11-22 | LENZ | AKKARAJU SRINIVAS | 10% | P - Purchase | $10.15 | +201.7K | 7.79M | +3% | +$2.05M |
| MI | 2021-10-15 | 2021-10-13+ | LENZ | Samsara BioCapital, L.P. | 10% | P - Purchase | $13.14 | +50.8K | 7.58M | +0.7% | +$667.7K |
| MI | 2021-10-08 | 2021-10-06+ | LENZ | AKKARAJU SRINIVAS | 10% | P - Purchase | $13.53 | +145.5K | 7.46M | +2% | +$1.97M |
| DMI | 2021-07-01 | 2021-06-29 | LENZ | AKKARAJU SRINIVAS | 10% | P - Purchase | $17.00 | +500.0K | 7.39M | +7% | +$8.50M |
| DMI | 2021-07-01 | 2021-06-29 | LENZ | AKKARAJU SRINIVAS | 10% | C - Cnv Deriv | — | +6.93M | 6.91M | New | — |
| D | 2021-07-01 | 2021-06-29 | LENZ | Lehrer-Graiwer Joshua | Pres AND CEO, Dir | C - Cnv Deriv | — | +8,126 | 1.16M | +0.7% | — |
| D | 2021-07-01 | 2021-01-16 | LENZ | Lehrer-Graiwer Joshua | Pres AND CEO, Dir | M - OptEx | $0.3 | +374.0K | 1.15M | +48% | +$112.2K |
| D | 2021-07-01 | 2021-06-29 | LENZ | KARSEN PERRY A | Dir | C - Cnv Deriv | — | +8,126 | 164.0K | +5% | — |
| D | 2021-07-01 | 2021-06-29 | LENZ | JIMENEZ JOSEPH | Dir | C - Cnv Deriv | — | +8,126 | 161.9K | +5% | — |
| D | 2021-07-01 | 2021-01-14 | LENZ | JIMENEZ JOSEPH | Dir | M - OptEx | $0.3 | +49.9K | 153.8K | +48% | +$15.0K |
| DM | 2021-07-01 | 2021-01-15+ | LENZ | Gutry Phil | Chief BUSINESS Off | M - OptEx | $0.5074 | +94.8K | 282.0K | +51% | +$48.1K |
| D | 2021-07-01 | 2021-06-29 | LENZ | Gutry Phil | Chief BUSINESS Off | C - Cnv Deriv | — | +8,126 | 293.5K | +3% | — |
| DI | 2021-07-01 | 2021-06-29 | LENZ | Shah Smital | Dir | P - Purchase | $17.00 | +5,882 | 5,882 | New | +$100.0K |
| DMI | 2021-07-01 | 2021-06-29 | LENZ | Jerel Davis | Dir, 10% | C - Cnv Deriv | — | +13.87M | 1.53M | New | — |
| DI | 2021-07-01 | 2021-06-29 | LENZ | Jerel Davis | Dir, 10% | P - Purchase | $17.00 | +180.0K | 1.71M | +12% | +$3.06M |
| D | 2021-07-01 | 2021-06-29 | LENZ | Stultz Katherine V | COO | C - Cnv Deriv | — | +8,126 | 216.0K | +4% | — |
| DI | 2021-07-01 | 2021-06-29 | LENZ | Versant Vantage II GP-GP, LLC | 10% | P - Purchase | $17.00 | +180.0K | 1.71M | +12% | +$3.06M |
| DI | 2021-07-01 | 2021-06-29 | LENZ | Versant Vantage II GP-GP, LLC | 10% | C - Cnv Deriv | — | +1.53M | 1.53M | New | — |
| D | 2021-07-01 | 2021-06-29 | LENZ | Versant Vantage II GP-GP, LLC | 10% | C - Cnv Deriv | — | +12.34M | 14.71M | +522% | — |
Purchase Sale Sale after option exercise All abbreviations